Johnson & Johnson $JNJ Shares Bought by Pin Oak Investment Advisors Inc.

Pin Oak Investment Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 3.7% in the second quarter, Holdings Channel.com reports. The fund owned 7,919 shares of the company’s stock after buying an additional 280 shares during the period. Johnson & Johnson makes up approximately 1.1% of Pin Oak Investment Advisors Inc.’s investment portfolio, making the stock its 22nd largest position. Pin Oak Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,313,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. W.H. Cornerstone Investments Inc. lifted its position in shares of Johnson & Johnson by 0.7% in the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after buying an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC raised its stake in Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after acquiring an additional 60 shares during the period. Ellis Investment Partners LLC lifted its holdings in Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after acquiring an additional 62 shares during the last quarter. Cypress Wealth Services LLC boosted its stake in Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after acquiring an additional 62 shares during the period. Finally, Horizon Bancorp Inc. IN grew its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.8%

JNJ stock opened at $199.39 on Tuesday. The firm’s 50-day moving average is $186.24 and its two-hundred day moving average is $170.46. The company has a market capitalization of $480.38 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $200.28. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Scotiabank initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price objective on the stock. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.